non-small cell lung cancer phenotype

Aliases

NSCLC

No related entities found.

Mentioned in (39)

Papers in which this entity is mentioned.

• Chromosomal instability as a driver of cancer progression. (2025)
• Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. (2024)
• Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. (2024)
• Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. (2023)
• A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. (2023)
• Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients (2023)
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. (2023)
• Towards understandings of serine/arginine-rich splicing factors. (2023)
• Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA. (2022)
• Spatially resolved whole transcriptome profiling in human and mouse tissue using Digital Spatial Profiling. (2022)
• Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. (2022)
• Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. (2021)
• Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
• Macrophage Polarization States in the Tumor Microenvironment. (2021)
• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. (2021)
• Immuno-genomic landscape of osteosarcoma. (2020)
• Neoadjuvant checkpoint blockade for cancer immunotherapy. (2020)
• Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. (2020)
• Determining cell type abundance and expression from bulk tissues with digital cytometry. (2019)
• Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. (2019)
• VCF2CNA: A tool for efficiently detecting copy-number alterations in VCF genotype data and tumor purity. (2019)
• Genome-wide cell-free DNA fragmentation in patients with cancer. (2019)
• Assessment of tumor mutation burden calculation from gene panel sequencing data. (2019)
• Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. (2018)
• Genome doubling shapes the evolution and prognosis of advanced cancers. (2018)
• Tumor fraction in cell-free DNA as a biomarker in prostate cancer. (2018)
• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2018)
• Patterns and mechanisms of structural variations in human cancer. (2018)
• Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (2017)
• OncoKB: A Precision Oncology Knowledge Base. (2017)
• Patient-derived xenografts undergo mouse-specific tumor evolution. (2017)
• Integrated digital error suppression for improved detection of circulating tumor DNA. (2016)
• The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. (2016)
• Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
• MBASED: allele-specific expression detection in cancer tissues and cell lines. (2014)
• Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. (2014)
• Fusion genes and their discovery using high throughput sequencing. (2013)
• A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. (2013)
• Massive genomic rearrangement acquired in a single catastrophic event during cancer development. (2011)

Merged raw entities (1)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.